Home

Jose-Carlos Gutierrez-Ramos

CIK 1667657 · SVP, Chief Science Officer · last filed 2026-08-06

Jose-Carlos Gutierrez-Ramos is a SVP, Chief Science Officer who has filed 44 SEC Form 4 insider transactions across 5 companies since 2016. The most recent filing, for DHR, was dated Aug 6, 2026. Across all open-market trades the lifetime net is −$1.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $6.9M across reported positions. 27 SEC filings were submitted jointly with DANAHER CORP /DE/.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$6.89M

Companies

5

Total Filings

44

Lifetime Open-Market Net

-$1.08M

Filer Profile

Reported Address
2200 PENNSYLVANIA AVE NW
SUITE 800W
WASHINGTON, DC 20037
Formerly Known As
Guiterrez-Ramos Jose Carlos (2016–2016)
Related Filers
DANAHER CORP /DE/ — 27 joint filings, latest 2026-08-06
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
DHR SVP, Chief Science Officer 32,495 $207.66 $6.75M -$268.9K 24 2026-08-06
BCYC Director 32,500 $4.30 $139.8K $0 6 2026-01-06
Evelo Biosciences, Inc. (EVLO) Delisted Director — $0.00 — $0 3 2023-06-12
MOMENTA PHARMACEUTICALS INC (MNTA) Delisted Director 0 — — -$814.5K 8 2020-10-01
SYNLOGIC, INC. (SYBX) Delisted See Remarks — $0.69 — $0 1 2018-03-16

Recent Filings

44 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-06 DHR Grant (A) +13,477 $0 EDGAR
2026-08-06 DHR Grant (A) +13,477 $0 EDGAR
2026-03-03 DHR Mixed +6,363 -$59.8K EDGAR
2026-02-25 DHR Tax (F) −344 -$72.0K EDGAR
2026-02-06 DHR Grant (A) +1,695 $0 EDGAR
2026-02-04 DHR Mixed −852 -$190.4K EDGAR
2026-01-06 BCYC Grant (A) +9,500 $0 EDGAR
2025-03-04 DHR Mixed −216 -$44.9K EDGAR
2025-02-25 DHR Tax (F) −586 -$123.7K EDGAR
2025-02-04 DHR Grant (A) — $0 EDGAR
Showing 1–10 of 44
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.